Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

Six months into Donald Trump’s second term, his administration is at war with the federal judiciary, evading court orders ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

Scientists have discovered the ability to “personalize” cancer treatments using cutting-edge genetic technology - but experts ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

Pediatrician Deborah Greenhouse writes that South Carolina is at risk because of the U.S. government’s decision to defund almost $500 million in mRNA vaccine research funding.